Uveal Neoplasms Market Report 2026

The uveal neoplasms market size has grown strongly in recent years. It will grow from $1.14 billion in 2025 to $1.2 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to improved ophthalmic diagnostic tools, expansion of specialized eye care centers, increased awareness of ocular tumors, availability of radiation-based therapies, growth in ophthalmic oncology expertise.

The uveal neoplasms market size is expected to see strong growth in the next few years. It will grow to $1.5 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing adoption of precision medicine in ophthalmology, rising investment in ocular oncology research, expansion of immunotherapy applications, growing demand for minimally invasive eye treatments, increasing use of advanced imaging diagnostics. Major trends in the forecast period include increasing adoption of targeted and immunotherapy treatments, rising use of advanced ocular imaging technologies, growing focus on early tumor detection, expansion of personalized treatment regimens, enhanced integration of multidisciplinary eye care.

The increasing incidence of eye cancer is expected to drive the growth of the uveal neoplasms market in the coming years. Eye cancer involves the abnormal growth of cells in the eye and can develop in various regions, including the retina, iris, or optic nerve. Factors contributing to the rising incidence include improved detection, environmental exposures, and aging populations. Uveal neoplasms, particularly uveal melanoma, are rare forms of eye cancer that can metastasize to other organs, especially the liver, posing serious health risks. For example, in 2023, Cancer Research UK, a UK-based cancer research organization, projected that eye cancer incidence rates in the UK would increase by 50% between 2023-2025 and 2038-2040, reaching an average of 3 cases per 100,000 people annually by 2038. Therefore, the rising incidence of eye cancer is driving the growth of the uveal neoplasms market.

Leading companies in the uveal neoplasms market are focusing on advanced liver-directed treatment approaches, such as percutaneous hepatic perfusion (PHP), to improve localized tumor control and minimize systemic toxicity. PHP is a minimally invasive procedure that isolates the liver’s blood supply to deliver high-dose chemotherapy directly into the hepatic artery while filtering blood exiting the liver, allowing concentrated treatment at the tumor site with reduced systemic exposure. For instance, in August 2023, Delcath Systems, Inc., a US-based interventional oncology company, received U.S. Food and Drug Administration (FDA) approval for HEPZATO KIT, a PHP-based therapy for metastatic uveal melanoma with unresectable liver-dominant metastases. The therapy features targeted melphalan infusion and extracorporeal filtration of hepatic blood, with treatment cycles typically repeated every 6-8 weeks as clinically appropriate. HEPZATO KIT enables higher local drug concentration with reduced systemic exposure and has demonstrated clinically meaningful benefits, including tumor response and disease control in eligible patients with metastatic uveal melanoma.

In August 2023, TriSalus Life Sciences, a US-based oncology company, merged with MedTech Acquisition Corporation for an undisclosed amount. The merger aims to strengthen TriSalus’ platform, enhancing treatments for liver and pancreatic cancers, including uveal melanoma with liver metastases. It is expected to accelerate technology development, drive sales growth, and secure funding for key initiatives through mid-2024. MedTech Acquisition Corporation is a US-based special purpose acquisition company (SPAC) focused on merging with businesses in the medical technology sector.

Major companies operating in the uveal neoplasms market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., IDEAYA Biosciences Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Verastem Oncology Inc., Iovance Biotherapeutics Inc., Immunocore Holdings PLC, Aura Biosciences, Foghorn Therapeutics Inc., Syncona Limited, iOnctura SA, Linnaeus Therapeutics, Inc., Delcath Systems Inc, Bellicum Pharmaceuticals Inc.

North America was the largest region in the uveal neoplasms market in 2025. The regions covered in the uveal neoplasms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the uveal neoplasms market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the uveal neoplasms market by increasing costs of imported ophthalmic imaging systems, radiation therapy equipment, oncology drugs, and diagnostic reagents. Eye hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported high-end diagnostic technologies, while Asia-Pacific faces higher treatment equipment costs. These tariffs are increasing diagnostic and treatment expenses and influencing procurement timelines. However, they are also encouraging local manufacturing of ophthalmic devices, regional research investments, and development of cost-effective treatment solutions.

The uveal neoplasms market research report is one of a series of new reports that provides uveal neoplasms market statistics, including uveal neoplasms industry global market size, regional shares, competitors with a uveal neoplasms market share, detailed uveal neoplasms market segments, market trends and opportunities, and any further data you may need to thrive in the uveal neoplasms industry. This uveal neoplasms market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Uveal neoplasms are tumors that form in the uveal tract of the eye, which comprises the iris, ciliary body, and choroid. These tumors can be benign (nevus) or malignant (uveal melanoma), potentially affecting vision and, in some cases, spreading to other organs.

The primary treatment types for uveal neoplasms include drugs and therapy. Uveal neoplasm drugs are medications used to treat tumors or cancerous growths in the uveal tract of the eye, including the iris, ciliary body, and choroid. These drugs are delivered via various routes, such as oral or injectable administration, and are distributed through channels including hospital pharmacies, online pharmacies, and retail pharmacies.

The uveal neoplasms market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and supportive services. The market value includes the value of related goods sold by the service provider or included within the service offering. The uveal neoplasms market also includes sales of diagnostic equipment, therapies, and pharmaceuticals. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.